Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
14%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
2
22%
Ph phase_3
4
44%
Ph phase_1
3
33%

Phase Distribution

3

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
4(44.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 22 (22.2%)
Phase 34 (44.4%)

Trials by Status

terminated111%
completed778%
not_yet_recruiting111%

Recent Activity

0 active trials
Showing 5 of 9
not_yet_recruitingphase_1

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

NCT05217498
terminatedphase_3

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

NCT00199381
completedphase_1

A Study to Evaluate Abuse Potential of Istradefylline

NCT02609477
completedphase_2

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

NCT00955045
completedphase_1

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

NCT02256033
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05217498Phase 1

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

Not Yet Recruiting
NCT00199381Phase 3

An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001

Terminated
NCT02609477Phase 1

A Study to Evaluate Abuse Potential of Istradefylline

Completed
NCT00955045Phase 2

A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Completed
NCT02256033Phase 1

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

Completed
NCT00203957Phase 3

Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa

Completed
NCT00957203Phase 3

Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients

Completed
NCT00455507Phase 2

A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Completed
NCT00955526Phase 3

Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9